Monday afternoon 4.45pm Peru: Thank you very much, Mr. Chair and good afternoon, dear colleagues. We’ve been working this afternoon just a few minutes ago on L3, Mr. Chair, and I’m happy to tell you that we have a good advance. We have an important number of para already agreed in informals. And even though …
Peru
Resolution L5. Strengthening information-sharing to increase international scheduling and the implementation of scheduling decisions
Monday afternoon session Chair: It is my pleasure to chair the session of this committee. And I’m confident that we would work together to bring the important work of the committee to good results in accordance with the agenda and organization of work contained in document L1. This committee would have eight meetings starting this …
Plenary Item 3. General debate (continued)
Peru: A very good afternoon. It is an honour for me to speak to this plenary hall. In Peru we are fighting against drug trafficking with a balanced and comprehensive approach and with full respect for human rights. Peru would like to reiterate its firm commitment to tackling the fight against drugs from a comprehensive, …
CND 65th Reconvened Session – 9th December 2022
Reconvened Sixty-fifth session of the Commission on Narcotic Drugs, Vienna, Austria, 8-9 December 2022 Chair: Welcome back. Secretariat: (Reminder on COVID safety measures in Vienna) Agenda item 4. – Strategic management, budgetary and administrative questions Chair: We considered our consolidated budget yesterday. We, as a commission, are now required to take action. There have been …
CND 65th Reconvened Session – 8th December 2022
Reconvened Sixty-fifth session of the Commission on Narcotic Drugs, Vienna, Austria, 8-9 December 2022 CCPCJ Chair: Good Morning. (Opening Statement) >>> CND dates 2023 March 13 – 17 CND Chair: Opening Statement (Agenda adopted) Agenda Item 4. Strategic management, budgetary and administrative questions, including the following sub-items: (a) Work of the standing open-ended intergovernmental working …
CND Chair one-day special forum on availability and access to controlled substances for medical and scientific purposes
Chair: I welcome our panelists. We all know how severe this issue is – medicines are unavailable or unaffordable. This is for a variety of reasons, some of it is regulatory – lets not forget that there is a lot of weork done to optimize legislation. There is also often a lack of professional knowledge. …